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alaria is the most widespread and relevant parasitic disease
orldwide; it is primarily transmitted by bites of Anopheles sp.,
ut can also be transmitted congenitally or through infected
lood transfusions. The major species infecting humans are
lasmodium falciparum and P. vivax. Even considering that both
pecies lead to severe disease, the ﬁrst has been traditionally
ssociated to more  deaths, mostly in the African continent.
o vaccine is available so far and the major control tools are
ased on early diagnosis and treatment, and vector control.
In Brazil, after the eradication campaign started in the
950s, malaria became restricted to the Amazon Region, which
espite representing 50% of the national territory holds no
ore  than 10% of the population. After the 1990s, due to better
ontrol of P. falciparum,  P. vivax became the main species, and is
esponsible for almost 85% of the reported cases, paralleling
he decrease in the overall fatality rate, the most successful
oal of the Brazilian Malaria Control Program.1 However, this
arasite is able to develop dormant stages (hypnozoites) in
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eserved.the liver leading to frequent relapses, thereby confounding
ofﬁcially reported data, since it is not possible to distinguish
new infections from relapse. With renewed interest in malaria
eradication in 2007, P. vivax became a signiﬁcant challenge as
no good tools are available to tackle hypnozoites and therefore,
relapse.2 In this context, uncommon ways of transmission
regain attention, such as transfusion-transmitted malaria,
which is capable of reintroducing the parasite in an area mov-
ing toward its elimination.
It is doubtless that transfusion-transmitted P. falciparum
malaria is a real danger to a patient, who may develop
severe disease and die. However, in areas such as the Amazon
region, where P. vivax predominates, there is a general con-
sensus, due to the misleading information that vivax malariaira Dourado, Av. Pedro Teixeira, 25, Dom Pedro, 69040-000 Manaus,
so problematic and therefore not much public health atten-
tion is given to this scenario. Recent data conclusively show
that P. vivax is actually associated to severe disease,3 namely
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amongst patients with comorbidities, which ﬁts precisely the
characteristics of blood transfusion recipients. Taking this into
account, it is possible that both vivax and falciparum endemic
areas deserve similar attention regarding the control of this
healthcare associated infection.
Other speciﬁc characteristics of P. vivax which make control
of transfusion-transmitted malaria even more  complicated
are: (1) faster acquisition of immunity, leading to more
asymptomatic cases that cannot be detected during epidemi-
ological screening in blood banks; (2) as P. vivax infects only
reticulocytes, parasitemia is usually low and therefore, less
likely to be detected by the routine thick blood smear exami-
nation; (3) frequent multiple relapses are detected essentially
through active case searches because clone-speciﬁc immu-
nity leads to asymptomatic relapse; (4) chloroquine resistance
(including reports from the Brazilian Amazon) is able to extend
periods of asymptomatic low parasitemia after beginning
treatment.2 Thus, donors implicated in this kind of transmis-
sion are often semi-immune, and with parasite levels below
the detection threshold of currently available assays at blood
banks. Furthermore, in many  endemic areas in Latin America,
malaria is becoming a disease of peri-urban areas, where the
population has been concentrated (rural exodus).4 This epi-
demiological transition takes Plasmodium carriers closer to
the urban blood banks, enabling more  and more  donations of
contaminated blood.
The dichotomy of this issue focuses either on the infec-
tion of the blood recipient if a less sensitive method is used
for Plasmodium screening, or on insufﬁcient blood stocks if
a more  rigid approach is adopted. In general, transfusion-
transmitted malaria does not call the attention of national
authorities. Since 2002, ofﬁcial data from Brazil reported only
four cases. Whether the very low number of cases is due to
under-reporting or not, is an issue that needs to be addressed.
There is no clear policy on the following up of blood recipients
in the Amazon, and since most of them already live in endemic
areas, new infections may not necessarily be reported as
transfusional. No matter what strategy is adopted to prevent
transfusion-transmitted malaria, it is likely that this kind of
transmission may still occur, and so malaria must always be
considered in any patient with a post-transfusion febrile ill-
ness.
In the non-Amazon area of Brazil, the policy is clear: no
patient coming from an endemic area is accepted as a donor.
However, recent data point to the occurrence of Plasmodium
positive blood in blood banks from the Brazilian Southeast.5 If
these samples come from travelers or from patients in contact
with the Atlantic Forest, where autochthonous Plasmodium is
occasionally found, is still a matter of debate.
In the Amazon area, epidemiological screening of poten-
tial donors has been traditionally adopted. Patients reporting a
conﬁrmed malaria infection in the past six months have their
donation declined, as well as patients coming from munic-
ipalities with an annual parasite index (API) higher than 49
cases/10,000 inhabitants.6,7 Moreover, since no quantitative
buffy coat test (QBC), a more  sensitive technique based on
the search of parasites stained with a ﬂuorescent dye in the
concentrated buffy coat, is available, some centers perform
the routine thick blood smear microscopy evaluation in all
samples. The major problems with this screening strategy is 2 0 1 4;3  6(6):385–387
that asymptomatic P. vivax relapses may occur even after six
months of the primary infection;2 API, despite being reliable
in Brazil, is not uniform throughout the whole municipality
and changes considerably from one year to the next (on-line
updated ofﬁcial data are not available to blood banks); the
thick blood smear is not as sensitive as to allow a proper detec-
tion of low parasitemia in asymptomatic patients, and the use
of rapid diagnostic tests is not different.
In the timely paper published by Freitas & Duarte in this
issue of the Revista Brasileira de Hematologia e Hemoterapia,8
the ﬁrst extensive evaluation of nine blood banks from
the Brazilian Amazon point to non-uniform and imprecise
adopted practices. The standardization of national policies is
urgent and the evaluated impact of these policies needs to be
shared with similar endemic areas throughout the world.
Maybe this is the right time to address more  aggres-
sive measures in the elimination of transfusion-transmitted
malaria, as part of a joint strategy to eliminate malaria from
endemic areas.9 The ﬁrst and most important thing to do is to
estimate the real burden of transfusion-transmitted malaria.
Therefore, better surveillance is urgently needed, both in the
many  malaria diagnostic posts spread throughout the Ama-
zon region and in blood banks. Screening for a recent blood
donation is recommended in malaria services. In blood banks,
thick blood smears are probably not the best diagnostic tool
for asymptomatic donors even if the number of read ﬁelds
in microscopy is increased, because it is time-consuming and
presents low sensitivity for this purpose. Many  studies have
suggested polymerase chain reaction (PCR) as a more  sensi-
tive tool to detect small concentrations of parasite DNA.10 New
techniques such as real-time PCR and loop mediated isother-
mal  ampliﬁcation (LAMP), with costs that have decreased in
the last few years, would be ideal in blood banks.11 Increasing
the volume of blood for DNA extraction, and PCR performed
in blood sample pools12 are interesting strategies as well,
however, the sensitivity of these techniques needs additional
evaluation. Serological markers have been abandoned as a
screening tool because of the low speciﬁcity, especially in
endemic areas. However, new epitopes are being discovered
as reasonably good markers of the asymptomatic popula-
tion in the Amazon.13 These more  speciﬁc markers need to
be addressed in blood banks, because of their lower costs
compared to PCR and because they are compatible with simi-
lar serologies already performed for other infectious diseases
in these settings. Furthermore, new methods are needed to
ensure transfusion safety without rejecting potential donors,
which would ensure safe transfusion without harming the
blood supply.14 Not a long time ago, gentian violet was added
to the blood to control transfusion-transmitted Chagas’ dis-
ease. The action against Plasmodium seems to be similar,15
but gentian violet has never been studied for this purpose.
The effects of gentian violet (with action against other para-
sites such as Toxoplasma, Trypanosoma and Leishmania or
even a wide spectrum) and the safety of antimalarial drugs on
blood components need to be revisited.
Malaria is under control in most of Latin America, however,
a new challenging goal is its elimination. Thus, all possi-
ble transmission routes need to be interrupted. In theory,
not many  private blood banks exist in the Brazilian Ama-
zon, which would make them the perfect scenario to test new
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trategies in terms of effectiveness and efﬁciency. That would
ubstantially add information to a neglected problem in most
. vivax endemic areas.
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